tella Inc. | Balance Sheet

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
1,080
1,749
899
710
1,518
Total Accounts Receivable
299
298
342
280
9
Inventories
4
9
20
20
2
Other Current Assets
160
130
93
253
93
Total Current Assets
1,544
2,186
1,354
1,262
1,622
Net Property, Plant & Equipment
464
473
431
18
22
Total Investments and Advances
256
489
289
196
235
Long-Term Note Receivable
-
-
18
13
-
Intangible Assets
100
166
77
1
-
Other Assets
-
2
79
207
47
Total Assets
2,387
3,397
2,377
1,538
1,880
ST Debt & Current Portion LT Debt
212
185
200
389
154
Accounts Payable
41
29
79
90
2
Income Tax Payable
13
11
6
28
14
Other Current Liabilities
86
140
146
140
156
Total Current Liabilities
352
365
432
647
325
Long-Term Debt
434
455
351
183
83
Provision for Risks & Charges
-
20
9
10
40
Deferred Taxes
22
1
4
-
-
Other Liabilities
71
54
88
88
88
Total Liabilities
858
897
886
928
536
Common Equity (Total)
1,468
2,418
1,446
523
1,344
Total Shareholders' Equity
1,468
2,418
1,446
523
1,344
Total Equity
1,529
2,500
1,492
609
1,344
Liabilities & Shareholders' Equity
2,387
3,397
2,377
1,538
1,880
Accumulated Minority Interest
61
82
46
87
-

About tella

View Profile
Address
Mitsuihanagiri Building, 1/F
Tokyo Tokyo 160
Japan
Employees -
Website http://www.tella.jp
Updated 09/14/2018
tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It also offers technology and know-how to medical institutions such as university hospitals and national hospitals. It operates through the following business segments: Cell Medicine, Medical Support, and Pharmaceuticals.